AI Article Synopsis

  • Psoriasis is a widespread chronic inflammatory skin condition affecting over 125 million people globally, with treatments tailored based on disease severity.
  • The study analyzed gene expression profiles from the GEO database to identify differentially expressed genes (DEGs) in mild and severe cases of psoriasis, revealing significant differences in gene regulation and related biological pathways.
  • Key findings included the identification of hub genes associated with each severity level, such as PL1N1 and TLR4 in mild psoriasis, and BUB1 and CDK1 in severe psoriasis, with new insights on the role of the gene CDC42 in the adaptive immune response in psoriasis.

Article Abstract

Psoriasis is a common chronic inflammatory skin disease affecting >125 million individuals worldwide. The therapeutic course for the disease is generally designed upon the severity of the disease. In the present study, the gene expression profile GSE78097, was retrieved from the National Centre of Biotechnology (NCBI)‑Gene Expression Omnibus (GEO) database to explore the differentially expressed genes (DEGs) in mild and severe psoriasis using the Affy package in R software. The Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways of the DEGs were analysed using clusterProfiler, Bioconductor, version 3.8. In addition, the STRING database was used to develop DEG‑encoded proteins and a protein‑protein interaction network (PPI). Cytoscape software, version 3.7.1 was utilized to construct a protein interaction association network and analyse the interaction of the candidate DEGs encoding proteins in psoriasis. The top 2 hub genes in Cytohubba plugin parameters were validated using immunohistochemical analysis in psoriasis tissues. A total of 382 and 3,001 dysregulated mild and severe psoriasis DEGs were reported, respectively. The dysregulated mild psoriasis genes were enriched in pathways involving cytokine‑cytokine receptor interaction and rheumatoid arthritis, whereas cytokine‑cytokine receptor interaction, cell cycle and cell adhesion molecules were the most enriched pathways in severe psoriasis group. PL1N1, TLR4, ADIPOQ, CXCL8, PDK4, CXCL1, CXCL5, LPL, AGT, LEP were hub genes in mild psoriasis, whereas BUB1, CCNB1, CCNA2, CDK1, CDH1, VEGFA, PLK1, CDC42, CCND1 and CXCL8 were reported hub genes in severe psoriasis. Among these, CDC42, for the first time (to the best of our knowledge), has been reported in the psoriasis transcriptome, with its involvement in the adaptive immune pathway. Furthermore, the immunoexpression of CDK1 and CDH1 proteins in psoriasis skin lesions were demonstrated using immunohistochemical analysis. On the whole, the findings of the present integrated bioinformatics and immunohistochemical study, may enhance our understanding of the molecular events occurring in psoriasis, and these candidate genes and pathways together may prove to be therapeutic targets for psoriasis vulgaris.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723513PMC
http://dx.doi.org/10.3892/ijmm.2020.4771DOI Listing

Publication Analysis

Top Keywords

severe psoriasis
20
psoriasis
14
mild severe
12
hub genes
12
genes
8
psoriasis vulgaris
8
proteins psoriasis
8
immunohistochemical analysis
8
dysregulated mild
8
mild psoriasis
8

Similar Publications

Introduction: Psoriasis is a chronic skin condition characterized by immune-mediated inflammation. Recent research suggests a possible interaction between infection and the immunopathogenesis of psoriasis. However, over the past 5 years, no significant new evidence has clarified the relationship between and skin diseases.

View Article and Find Full Text PDF

Background: No currently approved treatment for pediatric plaque psoriasis selectively targets interleukin (IL)-23. In adults, guselkumab (a selective IL-23 inhibitor targeting the p19 subunit) demonstrated substantial efficacy with a favorable safety profile in treating moderate-to-severe plaque psoriasis.

Objective: PROTOSTAR (NCT03451851) evaluated the efficacy and safety of guselkumab in pediatric patients with moderate-to-severe plaque psoriasis.

View Article and Find Full Text PDF

Methotrexate injections intralesionally as a treatment for psoriatic nails proved to be effective in large-scale studies as well as individual case reports, but the process is painful and time-consuming. The objective of this study was to compare the efficacy and safety of combined fractional CO2 laser (Fr. CO2) 10,600 nm and methotrexate gel versus methotrexate 1% gel alone in treatment of nail psoriasis.

View Article and Find Full Text PDF

Introduction: Hidradenitis suppurativa (HS) is a chronic skin disease marked by recurrent abscesses, sinus tracts, and scarring, often accompanied by systemic symptoms. Diagnosed clinically, HS affects around 0.4% of people in western populations, but standardized treatment options are limited, leading to inconsistent outcomes.

View Article and Find Full Text PDF

A Case of Severe Erythroderma in a Patient with Pustular Psoriasis.

Clin Pract Cases Emerg Med

November 2024

University of Utah, Department of Emergency Medicine, Salt Lake City, Utah.

Case Presentation: A female patient with a known history of pustular psoriasis presented with sub-acute development of diffuse erythema and scaling of the skin with areas of exfoliation consistent with erythroderma. She was ill appearing and required admission and aggressive treatment with steroid-impregnated wet dressings, topical emollients, analgesics, and systemic immunosuppressants.

Discussion: Erythroderma is a dermatologic emergency characterized by diffuse erythema and scaling spanning greater than 90% of skin surfaces and is associated with a mortality rate as high as 64%.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!